Cover Image
市場調查報告書

全球核醫學診斷市場 (SPECT、PET) :分析與預測 (2015年∼2020年)

Global Nuclear Medicine Diagnostics Market (SPECT and PET ) - Analysis and Forecasts (2016 - 2021)

出版商 Mordor Intelligence LLP 商品編碼 353811
出版日期 內容資訊 英文 185 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學診斷市場 (SPECT、PET) :分析與預測 (2015年∼2020年) Global Nuclear Medicine Diagnostics Market (SPECT and PET ) - Analysis and Forecasts (2016 - 2021)
出版日期: 2016年08月08日 內容資訊: 英文 185 Pages
簡介

全球核醫學診斷市場,預計至2019年達到176億美元,2014年∼2019年以 (CAGR) 12.29%的年複合成長率成長。

本報告提供全球核醫學診斷市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

目錄

  • 簡介
  • 調查手法
  • 摘要整理
  • 主要的推論
  • 市場概要與產業趨勢
  • 目前市場方案
  • 應用
  • 技術概要
  • 新的發展
  • 產業價值鏈分析
  • 波特的五力分析
  • 推動因素、阻礙因素、機會、課題分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場課題
  • 市場區隔
  • 各類型產品
  • SPECT
  • PET
  • 其他
  • 市場區隔 (各地區) :各地區的佔有率與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、北非
  • 南美
  • 競爭情形
  • M&A分析
  • 新產品的銷售
  • 契約、聯盟、夥伴關係
  • 主要供應商分析
  • Mallinckrodt
  • Lantheus Medical Imaging
  • IBA Group
  • Triad Isotope
  • Siemens Healthcare
  • NTP Radioisotopes
  • Bracco Pharma
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Nordion, Inc.
  • 太陽日酸
  • FUJIFILM Holdings
  • Eczacibasi-Monrol
  • Isotec, Inc.
  • Petnet Solutions, Inc.
  • 投資機會預測
  • 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global market for radioisotopes is estimated to be USD 8.55 billion in 2014 and is expected to reach USD 15.37 billion by the end of 2019. During this period of forecast, the market is expected to grow at a CAGR of 12.45%.

Global Nuclear Medicine Radioisotopes Market-Market Dynamics

The report details several factors driving and restraining the market. Some of these are listed below.

Drivers

Major driving factors for the growth of the market are:

  • Increasing demand for SPECT and PET analysis in radiopharmaceuticals
  • Development of better instruments
  • Newer computer-based procedures for image analysis and display
  • New 99mTc labeled agents for visualizing biologically significant events
  • Increasing use in clinical applications to study psychiatric disorders
  • Integration of X-Ray tomography (CT) into SPECT

Restraints

Some of the major constraints for the market are:

  • Shorter half-life of radioisotopes
  • High capital investment
  • Regulatory guidelines
  • Reimbursement issues

The market is segmented on the basis of the type of radioisotopes, application, and geography. On the basis of the type of radioisotopes, the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123), Fluorine-18, Rubidium-82 (RB-82) and others. By application, the market is segmented into cardiology, lymphoma, thyroid, neurology oncology, and others. By geography, the market is segmented into North America, Europe, and Asia-Pacific.

SPECT radioisotopes chemical form of thallous chloride has been the principle tracer used in myocardial perfusion imaging. Technetium-99m is the major radioisotope used in SPECT. Generally, technetium is produced in technetium generators. Tl-201 is used in myocardial perfusion studies, In-111 is used in prostate cancer, and Ga-67 is used in lymphoma diagnosis and treatment. The most commonly used radiotracer in PET imaging is F-18 fluorodeoxyglucose (FDG), a glucose analogue. FDG-PET scans have been more accurate than conventional imaging in the evaluation of many malignancies. The other radionuclide used is Rubidium-82.

PET imaging radioisotopes have many applications in clinical neurology, which involves movement disorders, epilepsy, brain tumors, dementia, stroke and neuronal plasticity. Future applications include early diagnosis of brain metastases, Parkinson syndromes and neurodegenerative disorders such as AD. The market for radioisotopes is expected to be larger in developing countries because of the increasing awareness among people for radioisotopes, increasing the incidence of chronic disease like cancer and increasing population.

Mergers and acquisitions of small and medium-sized manufacturers to enter the overseas market is a strategy adopted by multinational players.

Some of the key players in the market are:

  • Agfa-Gevaert N.V.
  • CardiArc Ltd.
  • Digirad Corporation
  • Gamma Medica Inc.
  • GE Healthcare
  • Hologic Inc.

What the Report Offers

  • Market definition global nuclear medicine radioisotopes market along with identification of key drivers and restraints for the market.
  • Market analysis for the nuclear medicine radioisotopes market with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their market share.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
  • A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
  • An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
  • Wide-ranging information provided about the leading market players and the major strategies adopted by them.

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Size Estimation

2. Research Methodology 3. Executive Summary

4. Market Overview

  • 4.1. Definition of radiopharmaceuticals
  • 4.2. Market Share Analysis
  • 4.3. Market Drivers
    • 4.3.1. Rising incidences of Cancer and Cardiac disorders
    • 4.3.2. Development of better instruments
    • 4.3.3. Increasing SPECT and PET applications
    • 4.3.4. Growing Patient awareness
  • 4.4. Market Restraints
  • 4.41. Strict Regulatory Issues
    • 4.4.2. Reimbursement Problems
  • 4.5. Opportunities
    • 4.5.1. Increasing Imaging Technologies
    • 4.5.2. Potential Radioisotopes in pipeline
  • 4.53. Increasing neurological applications
    • 4.5.4. Cyclotron based production

5. Market Segmentation

  • 5.1. By Type of Radioisotopes
    • 5.1.1. Technetium-99m(Tc-99m)
    • 5.1.2. Thallium-201(Tl-201)
    • 5.1.3. Iodine(I-123)
    • 5.1.4. Fluorine-18
    • 5.1.5. Rubidium-82(Rb-82)
    • 5.1.6. Iodine-131(I-131)
    • 5.1.7. Yttrium-90(Y-90)
    • 5.1.8. Samarium-153(Sm-153)
    • 5.1.9. Rhenium-186(Re-186)
    • 5.1.10. Lutetium-177(Lu-177)
    • 5.1.11. Radium-223(Ra-223) & Alpharadin
    • 5.1.12. Actinium-225(Ac-225)
    • 5.1.13. Lead-212(Pb-212)/Bismuth-212(Bi-212)
    • 5.1.14. Astatine-211(At-211)
    • 5.1.15. Radium-224(Ra-224)
    • 5.1.16. Thorium-227(Th-227)
    • 5.1.17. Cesium-131
    • 5.1.18. Iodine-125
    • 5.1.19. Palladium-103
    • 5.1.20. Iridium-192
    • 5.1.21. Others
  • 5.2. By Applications
    • 5.2.1. Oncology
    • 5.2.2. Cardiology
    • 5.2.3. Lymphoma
    • 5.2.4. Thyroid
    • 5.2.5. Neurology
    • 5.2.6. Others
  • 5.3. By Geography
    • 5.3.1. North America
      • 5.3.1.1. US
      • 5.3.1.2. Canada
      • 5.3.1.3. Mexico
    • 5.3.2. Europe
      • 5.3.2.1. UK
      • 5.3.2.2. Spain
      • 5.3.2.3. Germany
      • 5.3.2.4. Italy
      • 5.3.2.5. France
      • 5.3.2.6. Rest of Europe
    • 5.3.3. Asia-Pacific
      • 5.3.3.1. India
      • 5.3.3.2. China
      • 5.3.3.3. Japan
    • 5.3.4. Rest of the World

6. COMPETITIVE LANDSCAPE

  • 6.1. Acquisitions and mergers
  • 6.2. New product launch
  • 6.3. Agreements and collaborations

7. Company profiles

  • 7.1. Agfa-Gevaert N.V.
  • 7.2. CardiArc Ltd.
  • 7.3. Digirad Corporation
  • 7.4. Gamma Medica Inc.
  • 7.5. GE Healthcare
  • 7.6. Hologic Inc.
  • 7.7. Medx Inc.
  • 7.8. Naviscan Inc.
  • 7.9. Positron Corporation
  • 7.10. Segami Corporation
  • 7.11. Siemens Healthcare

8. Appendix

  • 8.1. Abbreviations
  • 8.2. Bibliography
  • 8.3. Disclaimer
Back to Top